AI Article Synopsis
- Exosomes from cancer cells contain tumor-specific molecules, facilitating communication with nearby or distant cells, and are being explored for their potential use in cancer diagnosis, particularly through long non-coding RNAs (lncRNAs).
- The study focused on identifying circulating exosomal lncRNAs—specifically FOXD2-AS1, NRIR, and XLOC_009459—from the serum of patients with colorectal cancer (CRC) compared to healthy individuals using advanced isolation and validation techniques.
- The findings reveal that these lncRNAs are significantly elevated in CRC patients, showing good diagnostic accuracy (AUC values between 0.660 and 0.743) individually, and an improved combined AUC of 0.736 for CRC diagnosis
Article Abstract
Background: Exosomes derived from cancer cells encapsulate various kinds of tumor-specific molecules and thus can interact with adjacent or distant cells to mediate information exchange. Long non-coding RNAs (lncRNAs) in exosomes have the potential as diagnostic and prognostic biomarkers in different types of cancers. The current study was aimed to identify circulating exosomal lncRNAs for the diagnosis of colorectal cancer (CRC).
Methods: Exosomes were isolated from the serum by ultracentrifugation and verified by transmission electron microscope (TEM), qNano, and immunoblotting. Exosomal lncRNAs FOXD2-AS1, NRIR, and XLOC_009459 were selected by lncRNA microarray and validated by qPCR in 203 CRC patients and 201 healthy donors. The receiver operating characteristic curve (ROC) was used to assess the diagnostic efficiency of serum exosomal lncRNAs.
Results: Exosomal FOXD2-AS1, NRIR, and XLOC_009459 (TCONS_00020073) levels were significantly upregulated in 203 CRC patients and 80 early-stage CRC patients compared to 201 healthy donors, possessing the area under the curve (AUC) of 0.728, 0.660, and 0.682 for CRC, as well as 0.743, 0.660, and 0.689 for early-stage CRC, respectively. Notably, their combination demonstrated the markedly elevated AUC of 0.736 for CRC and 0.758 for early-stage CRC, indicating their potential as diagnostic biomarkers for CRC.
Conclusions: Our data suggested that exosomal lncRNAs FOXD2-AS1, NRIR, and XLOC_009459 act as the promising biomarkers for the diagnostics of CRC and early-stage CRC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996089 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.618967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating Serum Exosomal Long Non-Coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as Diagnostic Biomarkers for Colorectal Cancer.
Front Oncol
March 2021
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Article Synopsis
- Exosomes from cancer cells contain tumor-specific molecules, facilitating communication with nearby or distant cells, and are being explored for their potential use in cancer diagnosis, particularly through long non-coding RNAs (lncRNAs).
- The study focused on identifying circulating exosomal lncRNAs—specifically FOXD2-AS1, NRIR, and XLOC_009459—from the serum of patients with colorectal cancer (CRC) compared to healthy individuals using advanced isolation and validation techniques.
- The findings reveal that these lncRNAs are significantly elevated in CRC patients, showing good diagnostic accuracy (AUC values between 0.660 and 0.743) individually, and an improved combined AUC of 0.736 for CRC diagnosis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!